Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Contact us
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st fl.), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
D-U-N-S: 362071645
-
- + 7 985 908 58 18 9am-6pm GMT+3
-
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- FDA Approves Qelbree (viloxazine) for the Treatment of ADHD
- FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
- FDA Approves Roszet (rosuvastatin and ezetimibe) to Reduce LDL-C in Hyperlipidemia and Homozygous Familial Hypercholesterolemia
- Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
- FDA Approves New Indication & New Product Formulation for Myrbetriq for Use in Children with Neurogenic Detrusor Overactivity (NDO)
News and press releases
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021, PRAC, 09/04/2021
- AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets, PRAC, 07/04/2021
- AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues, PRAC, 31/03/2021
- EU recommendations for 2021-2022 seasonal flu vaccine composition, , 30/03/2021
Drugs.com - Clinical Trials
- NIH Begins Study of Allergic Reactions to Moderna, Pfizer-BioNTech COVID-19 Vaccines April 7, 2021 -- A clinical...
- Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine CAMBRIDGE, Mass.--(BUSINESS...
- Johnson & Johnson Statement on U.S. COVID-19 Vaccine Manufacturing New Brunswick, NJ (April 3,...
- Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study Thursday, April 01,...